Director/PDMR Shareholding
29/09/2022 10:13
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220929:nRSc1735Ba&default-theme=true
RNS Number : 1735B Tissue Regenix Group PLC 29 September 2022
Tissue Regenix Group plc
("Tissue Regenix", the "Company" or "the Group")
Director/PDMR Shareholding
Tissue Regenix Group (AIM:TRX), the regenerative medical devices company,
announces that on 28 September 2022, Daniel Lee, Chief Executive Officer,
bought 2,000,000 Ordinary Shares in the Group at a price of 0.485 pence per
share for a total consideration of $10,409.41.
As a result, Daniel Lee holds 7,262,200 Ordinary Shares in the Company
representing 0.10% of the total issued share capital.
For more information:
Tissue Regenix Group plc www.tissueregenix.com (http://www.tissueregenix.com)
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Tel: +44(0)20 7710 7600
Ben Maddison / Nick Harland
Walbrook PR Ltd Tel: +44 (0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Daniel Lee
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Tissue Regenix Group plc
b) LEI 213800PNOD5UHQUFJI36
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1p each
Identification code GB00B5SGVL29
b) Nature of the transaction Purchase
c) Price(s) and volume(s)
Price(s) Volume(s)
0.485 2,000,000
d) Aggregated information
- Aggregated volume 2,000,000
- Price $10,409.41
e) Date of the transaction 28 September 2022
f) Place of the transaction London Stock Exchange, AIM Market
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field of
regenerative medicine. The company's patented decellularisation ('dCELL®')
technology removes DNA and other cellular material from animal and human soft
tissue leaving an acellular tissue scaffold which is not rejected by the
patient's body and can then be used to repair diseased or damaged body
structures. Current applications address many critical clinical needs in
sports medicine, foot and ankle, and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech
company that specializes in regenerative medicine and is dedicated to the
development of innovative osteoinductive and wound care scaffolds that enhance
healing opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general orthopaedic,
dental, and ophthalmological surgical procedures.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGCGDCBBDDGDC